Conclusion
DWP16001 caused glucosuria in a dose-dependent manner, and systemic exposure was observed after multiple doses. DWP16001 was well tolerated up to 5.0 mg after a single oral dose and up to 2.0 mg after multiple oral administrations.
What is already known about this subject :
Type 2 diabetes is the chronic metabolic disorder which prevalence has been increasing worldwide.
SGLT-2 inhibitor, the antidiabetic agent which inhibits reabsorption of glucose in the renal tubule, recommended in T2DM accompanied by cardiovascular disease.
What this study adds :
We studied the pharmacodynamics and pharmacokinetics of DWP16001, a novel SGLT-2 inhibitor under development.
This study proved the effect of DWP16001 as a potent SGLT-2 inhibitor. This finding may provide information for clinical research and combination with other antidiabetic agents.